Alpha Cognition Inc
ACOG
Rang in Aktien
#20221
Alpha Cognition Inc., a biopharmaceutical company, engages in the development... Alpha Cognition Inc., a biopharmaceutical company, engages in the development of treatments for patients suffering from neurodegenerative diseases in the United States and Canada. The company's commercial development program includes ZUNVEYL oral tablet formulation for treating Alzheimer's disease. Its pre-clinical development programs comprise ZUNVEYL in combination with memantine for the treatment of moderate-to-severe Alzheimer's disease; ALPHA-1062 sublingual formulation for acute pancreatitis; ALPHA-1062 intranasal formulation for the treatment of cognitive impairment with mild traumatic brain injury; and ALPHA-0602, ALPHA-0702, and ALPHA-0802 programs for the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis disease and spinal muscular atrophy. The company was founded in 2000 and is headquartered in Vancouver, Canada.
Aktienkurs
$8.45
Marktkapitalisierung
$131.24M
Veränderung (1 Tag)
3.17%
Veränderung (1 Jahr)
67.99%
Land
US
Handel Alpha Cognition Inc (ACOG)
Kategorie
Healthcare
EPS für Alpha Cognition Inc (ACOG)
EPS zum June 2026 TTM: $-0.40
Laut den aktuellen Finanzberichten und dem Aktienkurs von Alpha Cognition Inc beträgt das aktuelle EPS des Unternehmens (TTM) $-0.40. Am Ende des Jahres 2022 betrug das EPS $-0.18 ein Rückgang im Vergleich zu dem EPS von 2021, das $-0.37 betrug.
EPS-Verlauf von Alpha Cognition Inc von 2018 bis 2026
EPS am Ende jedes Jahres
| Jahr | EPS | ändert |
|---|---|---|
| 2026 (TTM) | $-0.40 | 166.67% |
| 2023 | $-0.15 | -16.67% |
| 2022 | $-0.18 | -51.35% |
| 2021 | $-0.37 | -61.46% |
| 2020 | $-0.96 | 357.14% |
| 2019 | $-0.21 | 672.06% |
| 2018 | $-0.03 | 0.00% |
EPS für ähnliche Unternehmen oder Wettbewerber
| Unternehmen | EPS | EPS-Differenz | Land |
|---|---|---|---|
| $17.32 | -4,430.00% |
US
|
|
| $-7.98 | 1,895.00% |
US
|
|
| $-5.29 | 1,222.50% |
AU
|
|
| - | - |
CH
|
|
| $27.74 | -7,035.00% |
NL
|
